… for the current approved therapeutic antibodies produced in … the carbohydrate components
of antibodies by bio- or chemical … generation of therapeutic antibodies and Fc-fusion proteins. …

… Fc engineering, IgG-FcRn interaction can be used to generate a variety of therapeutic antibodies
… PK of therapeutic mAb and Fc-fusion proteins. As a large and polar molecule, mAb and …

… neonatal Fc receptor (FcRn), which salvages the protein from being degraded in endosomes.
As an additional benefit, the Fc portion of Fc-fusion … of antibody and Fc-fusion therapeutics. …

… antibodies (mAbs) and Fc-fusion protein development to ensure proper safety and efficacy
profiles. Most therapeutic mAbs are of IgG class and contain a glycosylation site in the Fc …

… mobile phase turned out to be restricted to acidic therapeutic antibodies (pI < 7), while non-…
basic antibody products (pI > 7) [90]. However, the hyphenation of SEC with MS for Fc-fusion …

… Fc region of Fc-fusion proteins can bind to neonatal Fc receptor (FcRn) thereby rescuing it …
domains of Fc-fusions. The serum half-life of a typical IgG antibody is longer than Fcfusions (3 …

… Some FcRs found on adaptive immune cells may make better targets for Fc‐fusions
based on antibody classes other than IgG. For example, in the aforementioned monomeric …

… antibody-based therapeutics (including Fc-fusion proteins) in the commercial pipeline and
in development, mAbs represent the fastest growing category of antibody-based therapeutics …

… The platform technology of fragment crystallizable (Fc) fusion, in which the Fc region of an
antibody is genetically linked to an active protein drug, is among the most successful of a new …

… Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically
enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J. Immunol. …